Tanja H Kakebeeke1,2, Elisa Knaier1, Aziz Chaouch3, Jon Caflisch1, Valentin Rousson3, Remo H Largo1, Oskar G Jenni1,2. 1. Child Development Center, University Children's Hospital Zürich, Zürich, Switzerland. 2. Children's Research Center, University Children's Hospital Zürich, Zürich, Switzerland. 3. Division of Biostatistics, Institute of Social and Preventive Medicine, University Hospital, Lausanne, Switzerland.
Abstract
AIM: The aim of this cross-sectional study was to provide normative data for motor proficiency (motor performance and contralateral associated movements [CAMs]) in typically developing children between 3 years and 18 years of age using an updated version of the Zurich Neuromotor Assessment (ZNA-2). METHOD: Six-hundred and sixteen typically developing children between 3 years and 18 years of age were enrolled from day-care centres, kindergartens, and schools, and were tested using the ZNA-2 with improved items of the original battery. Motor proficiency was assessed on five components (fine motor tasks, pure motor tasks, static balance, dynamic balance, and CAMs) as a function of age and sex to determine centile curves for each task. Intraobserver, interobserver, and test-retest reliabilities were evaluated. RESULTS: Most ZNA-2 tasks featured a marked developmental trend and substantial interindividual variability. Test-retest reliability was generally high (e.g. static balance 0.67; CAMs 0.81; and total scores 0.84). INTERPRETATION: The ZNA-2 is a reliable and updated test instrument to measure motor proficiency in children from 3 to 18 years with improved properties for assessing motor performance. It allows continuous measurement without changing items for the entire age range; this feature of the ZNA-2 is unique and makes the instrument suitable for clinical purposes. The reduction of CAMs scoring simplifies the clinical procedure and increases its reliability. WHAT THIS PAPER ADDS: The Zurich Neuromotor Assessment, Second Edition (ZNA-2) provides new norms for motor proficiency in children between 3 years and 18 years. High reliabilities suggest that the revised test battery is a useful tool for assessing neuromotor development. Integration of a 'not able to perform' category makes the ZNA-2 suitable for clinical purposes.
AIM: The aim of this cross-sectional study was to provide normative data for motor proficiency (motor performance and contralateral associated movements [CAMs]) in typically developing children between 3 years and 18 years of age using an updated version of the Zurich Neuromotor Assessment (ZNA-2). METHOD: Six-hundred and sixteen typically developing children between 3 years and 18 years of age were enrolled from day-care centres, kindergartens, and schools, and were tested using the ZNA-2 with improved items of the original battery. Motor proficiency was assessed on five components (fine motor tasks, pure motor tasks, static balance, dynamic balance, and CAMs) as a function of age and sex to determine centile curves for each task. Intraobserver, interobserver, and test-retest reliabilities were evaluated. RESULTS: Most ZNA-2 tasks featured a marked developmental trend and substantial interindividual variability. Test-retest reliability was generally high (e.g. static balance 0.67; CAMs 0.81; and total scores 0.84). INTERPRETATION: The ZNA-2 is a reliable and updated test instrument to measure motor proficiency in children from 3 to 18 years with improved properties for assessing motor performance. It allows continuous measurement without changing items for the entire age range; this feature of the ZNA-2 is unique and makes the instrument suitable for clinical purposes. The reduction of CAMs scoring simplifies the clinical procedure and increases its reliability. WHAT THIS PAPER ADDS: The Zurich Neuromotor Assessment, Second Edition (ZNA-2) provides new norms for motor proficiency in children between 3 years and 18 years. High reliabilities suggest that the revised test battery is a useful tool for assessing neuromotor development. Integration of a 'not able to perform' category makes the ZNA-2 suitable for clinical purposes.
Authors: Tanja H Kakebeeke; Aziz Chaouch; Elisa Knaier; Jon Caflisch; Valentin Rousson; Remo H Largo; Oskar G Jenni Journal: Eur J Pediatr Date: 2019-02-07 Impact factor: 3.183
Authors: Jeffrey W Keller; Annina Fahr; Julia Balzer; Jan Lieber; Hubertus J A van Hedel Journal: J Neuroeng Rehabil Date: 2020-07-13 Impact factor: 4.262
Authors: Diego Rivera; Antonio García; Jose Eugenio Ortega; Bernardo Alarcos; Kevin van der Meulen; Juan R Velasco; Cristina Del Barrio Journal: JMIR Mhealth Uhealth Date: 2019-08-28 Impact factor: 4.773
Authors: Darryn A Atkinson; Laura Mendez; Natalie Goodrich; Sevda C Aslan; Beatrice Ugiliweneza; Andrea L Behrman Journal: Front Neurol Date: 2019-12-20 Impact factor: 4.003
Authors: Dan M Cooper; Gay L Girolami; Brenda Kepes; Annamarie Stehli; Candice Taylor Lucas; Fadia Haddad; Frank Zalidvar; Nitzan Dror; Irfan Ahmad; Antoine Soliman; Shlomit Radom-Aizik Journal: Pediatr Res Date: 2020-01-11 Impact factor: 3.756
Authors: Patricia Lannen; Hannah Sand; Fabio Sticca; Ivan Ruiz Gallego; Clara Bombach; Heidi Simoni; Flavia M Wehrle; Oskar G Jenni Journal: Front Hum Neurosci Date: 2021-01-20 Impact factor: 3.169
Authors: Flavia M Wehrle; Jon Caflisch; Dominique A Eichelberger; Giulia Haller; Beatrice Latal; Remo H Largo; Tanja H Kakebeeke; Oskar G Jenni Journal: Front Hum Neurosci Date: 2021-01-28 Impact factor: 3.169
Authors: Jeffrey W Keller; Julia Balzer; Annina Fahr; Jan Lieber; Urs Keller; Hubertus J A van Hedel Journal: Sci Rep Date: 2019-12-30 Impact factor: 4.379